• FLAG tag Peptide: Assay Design for Clean Biology

  2026-09-14

  The FLAG tag Peptide (DYKDDDDK) can do more than elute tagged proteins: it can help separate affinity, tag accessibility, and biological effects in recombinant protein assays. This article connects its molecular design with lessons from a 2025 oligodendrocyte study to develop more discriminating workflows.

• Ran Lactylation, SIRT1, and Astrocyte Polarization

  2026-09-14

  The reference study identifies a metabolic–epigenetic pathway in which lactate promotes Ran lactylation at lysine 123, enhances STAT3 nuclear transport, and drives protective A2-like astrocyte polarization after oxygen-glucose deprivation/reoxygenation. Its combination of lactate manipulation, lactylome discovery, genetic validation, and spinal cord injury modeling positions SIRT1-regulated non-histone lactylation as a testable mechanism in CNS repair research.

• Separating Proliferation Arrest from Cancer Cell Death

  2026-09-13

  Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer response. Its central contribution is a framework for distinguishing growth inhibition from cell killing, including their differing proportions and timing, which improves interpretation of in vitro cancer drug studies.

• miR-18a, ALOXE3, and Ferroptosis in Glioblastoma

  2026-09-12

  The reference study defines a miR-18a/ALOXE3 regulatory axis that promotes glioblastoma by weakening ferroptotic cell death and increasing migration through 12-HETE signaling. Its combination of human tumor analysis, genetic perturbation, orthotopic modeling, and pathway experiments provides a mechanistic framework for studying lipid metabolism and cell-state regulation in GBM.

• ML385 Workflow for NRF2 Pathway Research

  2026-09-11

  Build reproducible NRF2 inhibition experiments with ML385 across A549 cancer models, oxidative-stress assays, and ferroptosis workflows. This practical guide connects dose–time optimization with the reference study’s in vivo alcoholic liver disease model while emphasizing controls, formulation, and interpretation limits.

• CX-5461 Drives DNA Damage in Cervical Cancer

  2026-09-11

  A 2026 Biochemical Pharmacology study shows that CX-5461 suppresses cervical cancer cell growth through a mechanism linking RNA polymerase I inhibition to ATM/ATR signaling, DNA damage, and aberrant mitotic entry. The findings also support CX-5461–cisplatin combinations as a research strategy for examining treatment sensitization, including in models of platinum resistance.

• Tyrothricin: Membrane-Targeting Research Workflows

  2026-09-10

  Tyrothricin is a peptide antibiotic mixture for designing practical bacterial, fungal, and exploratory viral antimicrobial assays. This guide connects membrane-disruption measurements with organelle-aware controls inspired by recent trigeminal neurobiology research, while emphasizing fresh preparation, mass-based dosing, and orthogonal viability readouts.

• Mitomycin C Workflows for Cancer Research

  2026-09-10

  Mitomycin C combines DNA replication inhibition with strong utility in apoptosis signaling research, TRAIL-sensitization studies, and cancer-cell viability workflows. This guide translates its mechanism, formulation constraints, and quantitative response data into practical setup, optimization, and troubleshooting decisions.

• iPSC Precision Screening for Ultrarare Leigh-Like Disease

  2026-09-09

  Sequiera et al. developed a patient-specific iPSC platform to prescreen therapies for an ultrarare Leigh-like syndrome caused by poorly characterized ECHS1 variants. By combining disease-relevant cellular models, healthy and disease controls, drug testing, and metabolic follow-up, the study shows how personalized iPSC systems can reduce uncertainty before clinical-trial enrollment.

• LLY-507: SMYD2 Inhibitor Workflow Guide

  2026-09-09

  LLY-507 combines nanomolar biochemical potency with strong target selectivity for mechanism-led cancer and fibrosis experiments. This practical guide translates SMYD2 inhibition into cell-based, methylation, proliferation, apoptosis, and renal injury workflows while emphasizing controls and troubleshooting.

• Solanesol (B8776): Practical Workflow Guide

  2026-09-08

  Solanesol is a hydrophobic polyisoprenoid alcohol that helps researchers establish controlled DMSO-based workflows for membrane-related and biochemical assays. It should not be introduced directly into water- or ethanol-based systems, and solubilized preparations should be made fresh and handled with solvent-matched controls.

• Arsenic, Mitochondrial ROS, and the Blood-Testis Barrier

  2026-09-08

  This 2025 study identifies a mechanistic chain linking arsenic exposure to blood-testis barrier disruption: SIRT3 loss, mitochondrial ROS accumulation, integrated stress response activation, and reduced translation of junctional proteins. Its melatonin experiments further suggest that mitochondrial redox control can preserve barrier integrity and sperm production in arsenic-exposed mice.

• p53 Inhibition as a Test of Pain Plasticity

  2026-09-07

  A translational framework for using Cyclic Pifithrin-α hydrobromide as a mechanistic probe at the intersection of p53 stress signaling and the Ca2+-CGRP/SP–Piezo2 axis described in trigeminal neuralgia.

• Berberrubine and NAFLD: Metabolic and Microbiota Evidence

  2026-09-07

  The reference study identifies berberrubine (BRB), a major berberine metabolite, as an active contributor to protection against diet- and oleic-acid-associated NAFLD models. Its value lies in connecting hepatic glucose and lipid regulation with gut-microbiota remodeling, while also defining practical molecular and microbiome readouts for follow-up studies.

• CX-5461: A Decision Framework for Pol I Assays

  2026-09-05

  CX-5461 is an RNA polymerase I inhibitor that connects rRNA-transcription stress with DNA damage, mitotic catastrophe, senescence, and autophagy. This article provides a practical assay framework for distinguishing primary Pol I effects from downstream cancer-cell phenotypes.

8618 records 1/575 page Next 12345 下5页 Last page